Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO
BackgroundPatients’ experience of symptoms often goes undetected during consultation in an outpatient clinic, and the use of a patient-reported outcome measure (PRO) in such a setting could be useful to aid treatment decision-making. A new PRO measure, the HM-PRO (Hematological Malignancy Specific P...
Main Authors: | Pushpendra Goswami, Esther N. Oliva, Tatyana Ionova, Roger Else, Jonathan Kell, Adele K. Fielding, Daniel M. Jennings, Marina Karakantza, Saad Al-Ismail, Graham P. Collins, Stewart McConnell, Catherine Langton, Magda J. Al-Obaidi, Metod Oblak, Sam Salek |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2020.571066/full |
Similar Items
-
Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study
by: Pushpendra Goswami, et al.
Published: (2020-09-01) -
Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity
by: Pushpendra Goswami, et al.
Published: (2020-03-01) -
70th Anniversary of Hematology Clinic of Russian Scientific Research Institute of Hematology and Transfusiology
by: KM Abdulkadyrov
Published: (2016-04-01) -
Some hematological changes in chickens infected with ectoparasites in Mosul
by: T. M. Al-Saffar, et al.
Published: (2008-01-01) -
Hematological profile of patients with Acromegaly in Iraq
by: Khaleed J Khaleel, et al.
Published: (2015-01-01)